Biotechnology · Healthcare
Roland Kolbeck
Equibles does not estimate personal net worth.
Get an email with a short summary when Aclaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACRS alertsAbout Roland Kolbeck
Roland Kolbeck has spoken on 1 investor event across 1 company, most recently for Aclaris Therapeutics, Inc. on June 4, 2026. Aclaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aclaris Therapeutics, Inc. includes Neal Walker (CEO, Chairman and Board Member), Kevin Balthaser (CFO), Douglas Manion (COO and Board Member) and 5 others.
Roland Kolbeck on recent calls
“So, right, we read out our Healthy Volunteers SAD and MAD data, and the pharmacokinetics was quite good. We see duration of PK that takes us out to 16 weeks. And so just from a PK perspective, you know, we think we could dose this drug up to monthly.”
Affiliation history
-
Aclaris Therapeutics, Inc. (ACRS)
Proxy statement
CurrentStart not stated–present
Last confirmed April 23, 2026
Company network
Leadership on record at Aclaris Therapeutics, Inc.
- Neal Walker CEO, Chairman, Board Member
- Kevin Balthaser CFO
- Douglas Manion COO, Board Member
- Douglas Manion, M.D., FRCP (C) COO
- Hugh Davis COO, Board Member
- Andrew Schiff, M.D. Board Member
- Vincent Milano Board Member
- William Humphries Board Member